Dear Colleagues, The @OncoAlert 🚨Network Presents OUR Picks of TOP 🔟Abstracts to be Presented at #ASCO24 This List Curated by: #OncoAlertAF Leads : @ElisaAgostinett 🇧🇪 @to_be_elizabeth 🇮🇹 @weoncologists 🇺🇸 With our distinguished OncoAlert Faculty: @ErikaHamilton9 🇺🇸 @DrSGraff 🇺🇸 @E_de_Azambuja 🇧🇪 @hoperugo 🇺🇸 @stolaney1 🇮🇹 @matteolambe 🇮🇹 and @JaniceTNBCmets 🇮🇹 Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with HR+, HER2-low or HER2-ultralow metastatic breast cancer with prior endocrine therapy : Primary results from DESTINY-Breast06 (DB-06). Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202. DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC. Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy. Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial. Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): Updated survival results of DESTINY-Breast03. On-treatment (tx) dynamic circulating tumor DNA changes (∆ctDNA) associated with progression-free survival (PFS) and overall survival (OS) of patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA-3 (ML-3). @aftimosp @NicoleKuderer @FAndreMD @prat_aleix @jesusanampa @StoverLab @curijoey @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @raalbany @LoiSher @SirohiBhawna @chemobrainfog @jamecancerdoc @JavierCortesMD @paspears88 @MammaMiaMagazin #OncoAlertAF @nataliagandur @acampsmalea @MartaPerachino @heinrich_kat @BiagioRicciutMD @DenizCanGuven1 @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @dr_yakupergun @anmwongNZ

TODAY🚨 #OncoAlertColloquium How I Treat when I dont have the Resources ✅FREE REGISTRATION👉 ✅ STEP2: ACCESS Sunday 8, 2025 7AM🇺🇸EST & 1PM🇪🇺CET 8PM🇵🇭 9AM🇦🇷🇧🇷 2PM🇪🇬 ⭐️A PASSWORD IS NEEDED, hence REGISTRATION IS NEEDED ⭐️ #OncoAlertAF @nataliagandur @acampsmalea @BiagioRicciutMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @rooogerthat